This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

PATH Resources

Our online catalog indexes publications, presentations, and related resources for peers in our field.

43 Resources
43 Resources
43 Resources
    Date
  1. By giving to PATH’s One Billion Lives Fund you’re unlocking our innovative potential. This pool flexible dollars amplifies other funding sources in support of our most impactful work. It also covers mission-critical projects, lets us move nimbly on emerging ideas, and allows us to adapt to an ever-shifting global health landscape.
    Published: October 2019
    Type: Resource Page
  2. Hypoxemia, insufficient oxygen in the blood, affects millions of people each year suffering from a range of common conditions—including newborn complications, obstetric emergencies, and pneumonia. Because of the prevalence of hypoxemia, oxygen is one of the 30 high-priority lifesaving medicines for women and children included in the World Health Organization Model List of Essential Medicines. However, evidence suggests that nearly half of hospitals in low- and middle-income countries have inconsistent or no supply of oxygen, and only half have working pulse oximeters to measure the oxygen level in blood—a critical element of safe oxygen delivery. Unreliable access to safe oxygen is the result of many complex, interlocking market and health system issues. Working in close partnership with country stakeholders and industry members, PATH’s Increasing Access to Safe Oxygen and Maternal, Newborn, and Child Health (MNCH) Devices project aims to provide technical assistance and build capacity in support of oxygen delivery scale-up at the country level, with an eye toward expanding to other essential medical devices specifically for MNCH. This fact sheet provides an overview of this work.
    Published: October 2019
    Type: Resource Page
  3. This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on worldwide. (This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.)
    Published: August 2019
    Type: Resource Page
  4. This brief, developed by the Advancing Maternal Immunization (AMI) collaboration, describes the activities required in the near- and mid-to long-term to generate key evidence and achieve the necessary conditions for advancing respiratory syncytial virus (RSV) maternal immunization in low- and middle-income countries. It is a companion to AMI's Advancing RSV Maternal Immunization: A Gap Analysis Report, which describes the evidence, information, and policy needs of global and country decision-makers, public health program planners, and implementers who might be involved in decision-making and introducing maternal RSV vaccines.AMI is a collaboration of cross-sectoral experts convened by PATH and WHO with the purpose of advancing RSV maternal immunization.Related links:A Roadmap for Advancing RSV Maternal ImmunizationAdvancing Maternal ImmunizationAdvancing RSV Maternal Immunization: A gap analysis brief
    Published: May 2019
    Type: Resource Page
  5. Purpose: To provide health committees with visual aids on criteria for model families, including child development practices.Used by community health committees.Approved by the Provincial Health Directorate, Nampula, Mozambique.
    Published: May 2019
    Type: Resource Page
Load more